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INTRODUCTION
Overactive bladder (OAB), defined as increased frequency
and urgency with or without urge incontinence, is a very com-
mon condition, especially in middle-aged women, with a
reported incidence of approximately 17% of the general fe-
male population (1, 2). Since many women may consider OAB
as a natural aging phenomenon and thus do not seek treat-
ment, its actual prevalence may be even higher. Despite its
common occurrence, however, our understanding (3-5) of the
pathophysiology underlying the development of OAB has
remained elementary. It is managed most commonly by drug
therapy, followed by various behavioral interventions and,
less frequently, by surgical methods. Each of these methods,
however, has variable efficacy and adverse effects. Classically,
urge incontinence has been considered most important, being
the key index in treatment outcome assessments. However,
since the new consensus by the International Continence Soci-
ety on the diagnosis of OAB (6), the presence or absence of
actual urine leakage was regarded as less important. With the
adaptation of this new definition, the number of patients newly
diagnosed with OAB is expected to increase, emphasizing the
need to develop first-line interventions for their symptoms.
The three most commonly employed methods for treating
newly-diagnosed OAB are bladder training, anticholinergic
therapy and a combination of the two. Here we report a con-
trolled, randomized study comparing the clinical efficacy of
these three methods, for the purpose of determining the most
appropriate first-line therapeutic modality.
MATERIALS AND METHODS
Between May 2001 and April 2002, 139 women present-
ing with symptoms of urgency and frequency, with or with-
out urge incontinence, were prospectively enrolled in this
study. Inclusion criteria included being 18 yr of age or older,
having a urination frequency of 8 or more times per day, the
presence of urge symptoms that may or may not accompany
incontinence, symptom duration of 3 months or longer and
no prior history of treatment for OAB. We excluded patients
with active urinary tract infection, clinically significant stress
urinary incontinence, bladder outlet obstruction, interstitial
cystitis, glaucoma or megacolon. Also excluded were patients
with a maximal urine flow rate of less than 10 mL/sec or a
postvoid residual urine amount that was more than 30% of
the total amount voided on uroflowmetry.
Upon enrollment, patients were randomly assigned to blad-
der training (BT, n=46), tolterodine treatment (To, 2 mg twice
daily, n=47) or a combination of the two (Co, n=46). Each
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Effects of Bladder Training and/or Tolterodine in Female Patients
with Overactive Bladder Syndrome: A Prospective, Randomized Study
We compared the effects of bladder training and/or tolterodine as first line treatment
in female patients with overactive bladder (OAB). One hundred and thirty-nine female
patients with OAB were randomized to treatment with bladder training (BT), toltero-
dine (To, 2 mg twice daily) or both (Co) for 12 weeks. Treatment efficacy was mea-
sured by micturition diary, urgency scores and patients’ subjective assessment of
their bladder condition. Mean frequency and nocturia significantly decreased in all
treatment groups, declining 25.9% and 56.1%, respectively, in the BT group; 30.2%
and 65.4%, respectively, in the To group; and 33.5% and 66.3%, respectively in the
Co group (p<0.05 for each). The decrease in frequency was significantly greater
in the Co group than in the BT group (p<0.05). Mean urgency score decreased by
44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the im-
provement was significantly greater in the To and Co groups than in the BT group
(p<0.05 for each). Although BT, To and their combination were all effective in con-
trolling OAB symptoms, combination therapy was more effective than either method
alone. Tolterodine alone may be instituted as a first-line therapy, but may be more
effective when combined with bladder training.
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patient received a physical examination and uroflowmetry
with postvoid residual urine scan. In addition, each patient
kept a record of urgency scores, with 0 indicating no symp-
toms, 1 rarely, 2 occasionally, 3 often, and 4 all the time, and
a frequency-volume chart. At 12 weeks, satisfaction score was
assessed, with 0 representing fully satisfied, 1 much improved,
2 slightly improved, 3 no improvement, and 4 worsened; a
change of 2 points or more was considered symptom improve-
ment. The frequency-volume chart and a survey of adverse
effects of medication were repeated every 4 weeks.
Patients in the BT and Co groups were educated of the
bladder drills by a nurse specialist. Gross and functional anato-
my of the lower urinary tract and pelvis were demonstrated,
with instructions on how bladder drills can increase functional
bladder capacity and actual voiding habits. Each patient was
instructed to examine her frequency-volume chart to deter-
mine the longest interval she could initially hold urination
and sustain urge symptoms. Each patient was then taught
to increase this interval by 15-min increments, with the aim
of achieving a 3 to 4 hr interval and a voided volume of 300
to 400 mL. In addition, whenever urgency occurred, patients
were educated to perform Kegel exercises for symptom alle-
viation. All bladder drill education was performed by one
nurse specialist, who telephoned each patient every 2 weeks
to make sure she was following the exact drill taught. In the
Co group, the bladder drill was started at the same time as
the start of medication.
Of the 139 patients, 89 (64.0%) completed the 12 week
treatment regimen and were subjects of outcome analyses.
Voiding frequency, nocturia, urgency score before and after
the treatment, satisfaction score at 12 weeks and adverse events
were measured in the three groups. Student’s t-test was used
for statistical analysis, and p<0.05 was defined as statistically
significant.
RESULTS
Patient characteristics, including age, weight, symptom
severity and duration, parity, pretreatment uroflowmetry pro-
file, presence and degree of urge or stress incontinence, and
urgency score, were similar among the three treatment groups
(Table 1).
At 12 weeks, 26 patients (56.5%) in the BT group, 32 (68.1
%) in the To group, and 31 (67.4%) in the Co group had com-
pleted the protocol. Mean frequency in the three groups dec-
reased significantly, from 10.9 to 8.1 (25.9%) in the BT group,
from 11.6 to 8.1 (30.2%) in the To group, and from 11.9 to
7.9 (33.5%) in the Co group (p<0.05 each) (Fig. 1). Noctu-
ria also decreased significantly in the three groups, from 1.5
to 0.6 per night (56.1%) in the BT group, from 1.7 to 0.6
(65.4%) in the To group, and from 2.0 to 0.6 (66.3%) in
the Co group (p<0.05 each) (Fig. 2), as did urgency scores,
from 2.6 to 1.4 (44.8%) in the BT group, from 2.8 to 1.1
(62.2%) in the To group, and from 3.0 to 1.2 (60.2%) in the
Co group (p<0.05 each) (Fig. 3). When we compared these
changes among the three groups, we found that patients in
the Co group showed greater improvements in frequency and
urgency scores than did patients in the BT group (p<0.05
each), and that urgency scores in the To and Co groups show-
ed significantly greater improvement than in the BT group
(p=0.017 and p=0.021, respectively). No difference was ob-
served between the To and Co groups.
Satisfaction scores at 12 weeks did not differ among the
three groups, being 1.5 in the BT group, with improvement
in 53.9%; 1.4 in the To group, with improvement in 63.0%;
and 1.3 in the Co group, with improvement in 71.0%. No
adverse events were reported from the BT group, whereas 13
patients (40.6%) in the To group and 12 (38.7%) in the Co
group reported one or more adverse events (Table 2). Most of
the events were mild and well-tolerated, except that severe
dry mouth occurred in 2 patients from each group, which led
Bladder 
training
Tolterodine
Combined
therapy
No. of patients 26 32 31
Age (yr) 45.73±12.68 48.41±9.38 45.42±9.54
Body weight (kg) 55.73±9.08 56.09±6.30 53.39±7.23
Symptom duration (yr) 6.44±6.84 4.54±5.15 4.10±3.99
Parity 2.08±1.26 2.16±1.14 1.94±1.29
Maximum flow rate  20.35±8.44 22.56±4.94 21.19±4.96
(mL/sec)
Residual urine (mL) 9.08±22.56 7.59±12.39 6.42±10.16
Frequency 10.93±2.14 11.63±2.57 11.90±1.51
Nocturia 1.45±1.14 1.72±1.04 1.96±1.49
Urgency score 2.58±1.30 2.81±0.74 3.00±1.10
Table 1. Patient characteristics before treatment
Complication Tolterodine Combination
Dry mouth 7 (21.9%) 9 (28.9%)
Hesitancy 3 (9.4%) 2 (6.5%)
Decreased appetite/constipation 2 (6.3%) 2 (6.5%)
Headache 1 (3.1%) 0
Table 2. Adverse events associated with treatment
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Fig. 1. Changes in frequency after 12 weeks of treatment (*p<
0.05). Improvement in the Co group was higher than BT group
(
� p=0.027).
�
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them to discontinue medication (withdrawal rates, 6.3% and
6.5%, respectively).
DISCUSSION
Despite extensive research on the complicated interactions
involving the neural network of the cerebrum, sacral cord and
the detrusor, little is known regarding the pathologic process
that occurs during the development of OAB (4, 5, 7). Accord-
ingly, therapeutic approaches for OAB have been diverse, con-
sisting largely of medical therapy, but also including behav-
ioral interventions such as bladder training, pelvic floor mus-
cle exercises with or without biofeedback, and electrical stim-
ulation. Other therapeutic approaches have included neuro-
modulation of the sacral nerves, intravesical instillations of
antimuscarinics and bladder overdistention, with augmenta-
tion cystoplasty remaining as the last resort. Naturally, non-
invasive methods, including medical therapy and behavioral
intervention, have been the initial treatments of choice for
OAB symptoms.
Although it is not known how bladder drills control and
sustain OAB symptoms, it is believed that ill-trained voiding
habits leading to decreased bladder compliance by frequent
voiding are corrected by progressively increasing the voiding
interval, thus increasing the voided volume and the functional
bladder capacity. Retraining these patients to void at normal
intervals would restore compliance when capacity increases
and may contribute to symptom improvement (8-11). Obser-
vations on the electrical stimulation of the pelvic floor mus-
cles (12) have shown that, during electrical stimulation, hyper-
activity of the bladder was either diminished or completely
abolished. This mechanism has been exploited as part of blad-
der training regimens.
Clinically, bladder training has been shown to be effective
in the management of urgency and urge incontinence (8, 13-
15). When bladder training was compared with medical the-
rapy (200 mg flavoxate hydrochloride plus 25 mg imipra-
mine three times daily for 4 weeks), urge incontinence was
completely controlled in 84% of patients in the BT group,
with symptom relief in 76%, compared with 56% and 48%,
respectively, in the medication group (16). A larger study (17),
however, found that addition of behavioral interventions did
not seem to offer any additional benefit to medical therapy
(tolterodine) after 6 months. Urgency episodes and daytime
frequency decreased 83% and 27.3%, respectively, in the tol-
terodine group, compared with 78.7% and 23%, respectively,
in the combination group. Improvements in patients’ percep-
tion of urinary symptoms were reported by 85.9% of the tol-
terodine group and 81.7% of the combination group. 
We found that all patients, a homogeneous group of female
patients, regardless of treatment methodology, reported sig-
nificant improvements in all voiding parameters examined,
but that the addition of medication to BT resulted in addi-
tional improvements in urgency and frequency. Our finding
of better outcomes in the Co than in the To group may be due
to the bladder training program and design used here, which
was a short-term intensive course of bladder drills. As many
authors have emphasized, patients’ understanding and com-
pliance are the key factors in bladder training. Accordingly,
the exercise program that we used did not simply require
patients to contract and relax their pelvic floor muscles for
certain periods of time. Instead, patients were given specific
goals of 15 min each in sustaining contractions and were ins-
tructed how to increase these intervals. Having such a specific
aim of what to accomplish with each exercise must have been
enforcing and rewarding as well. In addition, repeated instruc-
tions, confirmation and reassurance were essential and con-
stantly encouraged patients to stay on the right track for 12
weeks. 
Similar results have been reported (18), in which patients
were provided with written information sheets describing
the aims and endpoints of therapy as well as specific instruc-
tions on bladder drills. Although there were no formal blad-
der training sessions or additional follow-up for those in the
bladder training-only group, the self-explanatory information
sheets the patients kept would have reinforced and encour-
aged patients while on bladder drills. Thus, patients on med-
ication plus bladder training reported significantly better
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Fig. 2. Changes in nocturia after 12 weeks of treatment (*p<0.05).
Changes in nocturia did not differ among the groups.
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Fig. 3. Changes in urgency scores after 12 weeks of treatment
(*p<0.05). Improvement in To group (
� p=0.017) and Co group
(
� p=0.021) was higher than BT group.
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results after therapy than did patients on medication alone.
In the previous study, in which the drills were simplified, it
may have facilitated patient adherence to treatment, but with-
out any further reinforcements, the therapeutic benefits of
BT may have been compromised (17). In this study, we found
that patient adherence to treatment was lowest and discon-
tinuation rate highest in the BT group, although the treat-
ment efficacy results were similar at the end of 12 weeks. This
may be attributed to the longer duration of patient maneu-
vering required before experiencing significant improvement
in this BT-only group. Thus, despite many efforts by the phy-
sician to make patients stay on the correct treatment regimen,
it was evidently easier for patients to take medication twice a
day than to repeat exercises many times a day for months. 
We noted no adverse effects in the BT group, whereas, in
the other 2 groups, the most common adverse effect was dry
mouth. We found that 6.3% of patients in the BT group and
6.5% in the Co group had to discontinue medication due to
severe dry mouth, percentages lower than those previously
reported (19, 20). These results indicate that 4 mg/day tolte-
rodine is safe and does not require dose adjustment.
From these results, we conclude that bladder training, tol-
terodine and the combination of the two are all effective in
controlling OAB symptoms, with comparable patient satis-
faction. Since a short-term intensive course of bladder drill
is as effective as medical or combined therapy in all voiding
symptoms, but does not have any adverse effects, bladder train-
ing can be safely and effectively employed as first line treat-
ment for OAB. In patients who have predominantly symp-
toms of frequency or urgency, tolterodine may be more effec-
tive, especially when combined with bladder training. 
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